TCG Crossover Management, LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), TCG Crossover Management, LLC reported 36 stock positions worth $1.2 billion. Its top holding was CG Oncology (CGON) at 11.7% of the portfolio, followed by Dyne Therapeutics (DYN, 8.1%) and Cogent Biosciences (COGT, 6.4%). Compared with Q2 2024, it opened 9 new positions, sold out of 5, added to 2 and reduced 4. The biggest buy was a new position in Xencor (XNCR) and the biggest sale an exit from Madrigal Pharmaceuticals (MDGL).
- Most Recent 13F
- Q2 2026
- Location
- PALO ALTO, CA
- CIK
- 0001839948
- Portfolio Value
- $1.2B (Q3 2024)
- SEC Filing
- 0001214659-24-019064 ↗ filed Nov 14, 2024
Holdings Value
Holdings 36 stocks · $1.2B
| CGON CG Oncology Inc. | 11.73% | 3,670,206 | $138.5M | No change |
| DYN Dyne Therapeutics Inc. | 8.07% | 2,650,150 | $95.2M | No change |
| COGT Cogent Biosciences Inc. | 6.37% | 6,964,375 | $75.2M | No change |
| ABVX Abivax SA-ADR | 5.91% | 6,056,596 | $69.8M | No change |
| EWTX Edgewise Therapeutics Inc. | 4.78% | 2,112,984 | $56.4M | Reduce -7.0% |
| SLN Silence Therapeutics PLC-ADR | 4.67% | 3,033,560 | $55.2M | Reduce -7.9% |
| SVRA Savara Inc. | 4.44% | 12,362,205 | $52.4M | No change |
| KROS Keros Therapeutics Inc. | 4.33% | 879,344 | $51.1M | No change |
| XNCR Xencor Inc. | 4.14% | 2,427,138 | $48.8M | New |
| TYRA Tyra Biosciences Inc. | 3.96% | 1,989,103 | $46.8M | No change |
| GPCR Structure Therapeutics Inc. | 3.95% | 1,063,000 | $46.7M | Add +53.0% |
| OCUL Ocular Therapeutix Inc. | 3.92% | 5,319,148 | $46.3M | No change |
| CNTA Centessa Pharmaceuticals Ltd. | 3.92% | 2,890,816 | $46.2M | No change |
| TRML Tourmaline Bio Inc. | 3.22% | 1,477,593 | $38.0M | No change |
| THRD Third Harmonic Bio Inc. | 2.77% | 2,415,000 | $32.7M | New |
| ATXS Astria Therapeutics Inc. | 2.58% | 2,761,861 | $30.4M | No change |
| MLYS Mineralys Therapeutics Inc. | 2.53% | 2,470,265 | $29.9M | Reduce -22.4% |
| KURA Kura Oncology Inc. | 2.36% | 1,423,642 | $27.8M | No change |
| SLNO Soleno Therapeutics Inc. | 2.35% | 550,000 | $27.8M | New |
| CMPS Compass Pathways PLC | 2.06% | 3,858,000 | $24.3M | No change |
| IRON Disc Medicine Inc. | 2.03% | 486,957 | $23.9M | No change |
| FULC Fulcrum Therapeutics Inc. | 1.59% | 5,250,000 | $18.7M | New |
| MBX MBX Biosciences Inc. | 1.43% | 650,000 | $16.9M | New |
| AMLX Amylyx Pharmaceuticals Inc. | 1.27% | 4,643,812 | $15.0M | New |
| ADVM Adverum Biotechnologies Inc. | 1.19% | 2,008,339 | $14.1M | New |
| TRDA Entrada Therapeutics Inc. | 0.79% | 584,955 | $9.3M | No change |
| VTGN Vistagen Therapeutics Inc. | 0.68% | 2,676,580 | $8.1M | New |
| TARS Tarsus Pharmaceuticals Inc. | 0.65% | 231,820 | $7.6M | Reduce -58.3% |
| EYPT Eyepoint Inc. | 0.62% | 922,335 | $7.4M | No change |
| NKTR Nektar Therapeutics | 0.44% | 4,000,000 | $5.2M | No change |
| AEROVATE THERAPEUTICS INC | 0.40% | 2,240,809 | $4.7M | No change |
| AVTX Avalo Therapeutics Inc. | 0.39% | 483,000 | $4.6M | New |
| KOD Kodiak Sciences Inc. | 0.22% | 1,008,158 | $2.6M | Add +12.0% |
| ANTX AN2 Therapeutics Inc. | 0.14% | 1,555,118 | $1.7M | No change |
| VTYX Ventyx Biosciences Inc. | 0.06% | 316,195 | $689K | No change |
| CABA Cabaletta Bio Inc. | 0.03% | 86,795 | $410K | No change |
Portfolio Sells Q2 2024 → Q3 2024
| MDGL Madrigal Pharmaceuticals Inc. | Sold out | 0.00% | −4.36 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −2.34 |
| SLN Silence Therapeutics PLC-ADR | Reduce -7.9% | 4.67% | −1.85 |
| ADVM Adverum Biotechnologies Inc. | Sold out | 0.00% | −1.44 |
| MLYS Mineralys Therapeutics Inc. | Reduce -22.4% | 2.53% | −1.35 |
| VTGN Vistagen Therapeutics Inc. | Sold out | 0.00% | −0.97 |
| TARS Tarsus Pharmaceuticals Inc. | Reduce -58.3% | 0.65% | −0.93 |
| CCCC C4 Therapeutics Inc. | Sold out | 0.00% | −0.61 |
| EWTX Edgewise Therapeutics Inc. | Reduce -7.0% | 4.78% | +0.51 |
Portfolio Buys Q2 2024 → Q3 2024
| XNCR Xencor Inc. | New | 4.14% | +4.14 |
| THRD Third Harmonic Bio Inc. | New | 2.77% | +2.77 |
| SLNO Soleno Therapeutics Inc. | New | 2.35% | +2.35 |
| FULC Fulcrum Therapeutics Inc. | New | 1.59% | +1.59 |
| MBX MBX Biosciences Inc. | New | 1.43% | +1.43 |
| AMLX Amylyx Pharmaceuticals Inc. | New | 1.27% | +1.27 |
| ADVM Adverum Biotechnologies Inc. | New | 1.19% | +1.19 |
| GPCR Structure Therapeutics Inc. | Add +53.0% | 3.95% | +1.11 |
| VTGN Vistagen Therapeutics Inc. | New | 0.68% | +0.68 |
| AVTX Avalo Therapeutics Inc. | New | 0.39% | +0.39 |
| KOD Kodiak Sciences Inc. | Add +12.0% | 0.22% | +0.00 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 54 | $4.2B | ABVX, TNGX, CGON, COGT, IMVT |
| Q1 2026 | 49 | $3.5B | ABVX, CGON, TNGX, COGT, CNTA |
| Q4 2025 | 43 | $3.0B | ABVX, COGT, CGON, TNGX, CNTA |
| Q3 2025 | 40 | $2.0B | ABVX, CGON, COGT, AMLX, CNTA |
| Q2 2025 | 37 | $875.5M | CGON, TNGX, COGT, OCUL, CDTX |
| Q1 2025 | 37 | $733.1M | CGON, COGT, CNTA, MLYS, OCUL |
| Q4 2024 | 38 | $1.0B | CGON, DYN, XNCR, COGT, CNTA |
| Q3 2024 | 36 | $1.2B | CGON, DYN, COGT, ABVX, EWTX |
| Q2 2024 | 32 | $959.5M | CGON, DYN, ABVX, SLN, COGT |
| Q1 2024 | 33 | $1.3B | CGON, DYN, ATXS, SLN, GPCR |